Montanide ISA-51/peptide 946-tetanus peptide conjugate melanoma vaccine

Known as: ISA-51/p946-Tet p, ISA-51/p946/Tet p, Montanide ISA-51/Peptide 946 melanoma vaccine/Tetanus peptide melanoma vaccine 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2014
0120042014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Slow-release delivery has great potential for specifically targeting immune-modulating agents into the tumor-draining area. In… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
A central goal in vaccinology is the induction of high and sustained Ab responses. Protein-in-adjuvant formulations are commonly… (More)
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
BACKGROUND A prophylactic vaccine for hepatitis C virus (HCV) requires generation of strong humoral as well as CD4(+) and CD8… (More)
Is this relevant?
2004
2004
Previous studies in small groups of patients suggested that immunization of melanoma patients with peptide epitopes recognized by… (More)
  • table 2
  • table 3
  • figure 1
Is this relevant?